Shots:

• Debiopharm to receive $226M up front- ~$853.7M as regulatory and commercial milestones along with royalties. The transaction is expected to close in early Q2’21
• Merck KGaA get an exclusive right to develop and commercialize xevinapant globally- including in the US and will co-fund the ongoing P-III TrilynX study that involves assessing Xevinapant vs PBO in 700 patients in combination with CRT in cisplatin-eligible patients with high-risk LA SCCHN
• Xevinapant has received the FDA’s BTD in Feb 2020- based on the P- II results that showed xevinapant + CT reduced risk of death by 51% vs SOC in this patient with high-risk LA SCCHN

 ­ Ref: PRNewswire | Image: Merck KGaA